What hormones serve as counter‑regulatory mechanisms during hypoglycemia?

Hypoglycemia Counter-Regulatory Hormones

The critical counter-regulatory hormones during hypoglycemia are, in hierarchical order: (1) decreased insulin secretion, (2) increased glucagon secretion, and (3) increased epinephrine secretion when glucagon is absent, with cortisol and growth hormone contributing during prolonged hypoglycemia 1.

Primary Defense Mechanisms

The physiological defense against falling glucose operates in a specific sequence as plasma glucose declines:

First Line: Insulin Suppression

• Occurs within the physiological glucose range as levels begin to fall
• Insulin secretion becomes virtually completely suppressed at glucose ≤55 mg/dL
• At this threshold, plasma insulin drops below 3 µU/mL, C-peptide below 0.6 ng/mL 1

Second Line: Glucagon

• Activates as glucose drops just below the physiological range
• Most important hormone for acute glucose counterregulation 2
• Rapid onset of insulin-antagonistic effects
• In type 1 diabetes and advanced type 2 diabetes, this response is lost due to β-cell failure and absence of intraislet insulin signaling 1

Third Line: Epinephrine (Critical Backup)

• Becomes the dominant counterregulatory hormone when glucagon response is deficient
• Activates at the same glucose threshold as glucagon (just below physiological range)
• Rapid onset of glucose-raising effects
• Persons with type 1 diabetes are critically dependent on this defense since their insulin and glucagon responses are compromised 1
• In diabetes, this response is often attenuated by recent antecedent hypoglycemia, prior exercise, or sleep—shifting the glycemic threshold lower 1

Fourth Line: Cortisol and Growth Hormone

• Involved in defense against prolonged hypoglycemia only
• Delayed onset—insulin-antagonistic effects appear only after several hours 1, 2
• Less critical for acute glucose recovery but important for sustained counterregulation

Clinical Implications in Diabetes

Hypoglycemia-Associated Autonomic Failure (HAAF)

The guideline emphasizes a critical syndrome where:

• Recent antecedent hypoglycemia (within 2-3 weeks) shifts sympathoadrenal activation thresholds lower
• Attenuated epinephrine response increases severe hypoglycemia risk by 25-fold or more when combined with absent insulin/glucagon responses 1
• Reduced sympathetic neural response causes hypoglycemia unawareness, increasing severe hypoglycemia risk 6-fold 1

Key clinical point: 2-3 weeks of scrupulous hypoglycemia avoidance can reverse hypoglycemia unawareness and improve epinephrine responses in most affected patients 1

Progression in Type 2 Diabetes

• Early type 2 diabetes: insulin and glucagon responses remain intact
• Advanced type 2 diabetes with absolute insulin deficiency: develops the same defective counterregulation as type 1 diabetes 1
• Risk of HAAF increases progressively as β-cell failure advances over years

Behavioral Defense

Carbohydrate ingestion is the behavioral defense, prompted by neurogenic symptoms (mediated by sympathetic neural activation) that typically develop at mean plasma glucose ~55 mg/dL 1. This defense fails when hypoglycemia unawareness develops from attenuated sympathetic responses.